CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

A Novel Familial Cardiac Arrhythmia Syndrome with Widespread ST-Segment Depression Screening for Cardiovascular Disease Risk With Electrocardiography: US Preventive Services Task Force Recommendation Statement Percutaneous coronary intervention using a combination of robotics and telecommunications by an operator in a separate physical location from the patient: an early exploration into the feasibility of telestenting (the REMOTE-PCI study) Sudden Cardiac Arrest Survivorship: A Scientific Statement From the American Heart Association Digital learning and the future cardiologist Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials JACC Scientific Expert Panel Management of No-Reflow Phenomenon in the Catheterization Laboratory Plaque progression assessed by a novel semi-automated quantitative plaque software on coronary computed tomography angiography between diabetes and non-diabetes patients: A propensity-score matching study Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial Use of High-Risk Coronary Atherosclerotic Plaque Detection for Risk Stratification of Patients With Stable Chest Pain: A Secondary Analysis of the PROMISE Randomized Clinical Trial

Original Research2021 Mar 9.

JOURNAL:Diabetes Obes Metab. Article Link

Red Cell Distribution Width in Patients with Diabetes and Myocardial Infarction: an analysis from the EXAMINE trial

JP Ferreira, Z Lamiral, G Bakris et al. Keywords: alogliptin; outcomes; red cell distribution width; T2DM

ABSTRACT

BACKGROUND - Red blood cell distribution width (RDW) is a measure of size variability in the red blood cell population (anisocytosis). Increased RDW may arise from any condition that affects erythropoiesis or the survival of erythrocytes. RDW has been associated with poor prognosis in patients with type 2 diabetes (T2D). Whether RDW is a risk marker for adverse cardiovascular outcomes or also a marker of noncardiovascular health concerns is of clinical importance.

 

AIMS - To determine the clinical correlates of increased RDW, its potential mechanistic association with multiple circulating biomarkers, and its prognostic value, in patients with (T2D) who had a recent acute coronary syndrome.

 

METHODS - We used timeupdated Cox models applied to patients enrolled in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.

 

RESULTS - A total of 5380 patients were included, the median age was 61 years and 32% were women. Patients with higher RDW were older, more frequently women, with longer duration of diabetes duration, and increased comorbidities. An RDW >16.1% (both baseline and timeupdated) was independently associated with the study primary composite outcome of nonfatal myocardial infarction, nonfatal stroke or cardiovascular death (timeupdated adjusted HR =1.36, 95%CI =1.161.61, p < 0.001), allcause death (timeupdated adjusted HR =2.01, 95%CI =1.602.53, p < 0.001), as well as mortality from nonCV causes (timeupdated adjusted HR =2.67, 95%CI =1.724.15, p < 0.001). RDW had a weaktomoderate correlation with hemoglobin and circulating markers that reflected inflammation, apoptosis, fibrosis and congestion. Alogliptin did not alter RDW values.

 

CONCLUSIONS - RDW is a marker of disease severity associated with a multitude of poor outcomes, including both cardiovascular and noncardiovascular death. RDW correlated modestly with inflammatory, proapoptotic, profibrotic, and congestion markers, and its levels were not affected by alogliptin during the course of the trial.

 

This article is protected by copyright. All rights reserved.